Stockscreener 앱 받기
1.98
1.54%
0.03
시간 외 거래:
2.03
0.05
+2.53%
전일 마감가:
$1.95
열려 있는:
$2
하루 거래량:
116.57K
Relative Volume:
0.38
시가총액:
$51.64M
수익:
$1.79M
순이익/손실:
$-70.90M
주가수익비율:
-0.1274
EPS:
-15.54
순현금흐름:
$-34.95M
1주 성능:
+0.51%
1개월 성능:
-7.04%
6개월 성능:
-55.70%
1년 성능:
-18.85%
1일 변동 폭
$1.98
$2.06
1주일 범위
$1.80
$2.08
52주 변동 폭
$1.5201
$16.94
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Inc
전화
(650) 382-3281
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
SNTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.98 | 51.38M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Laidlaw | Buy |
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
What analysts say about Senti Biosciences Inc. stockRapid wealth accumulation - Autocar Professional
Solid Biosciences Inc. shares rise 3.29% premarket after Senti Bio's presentation at BioScience Forum. - AInvest
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum - The Manila Times
Senti Bio to present logic-gated CAR-NK cell therapy at BioScience Forum - Investing.com
Why Senti Biosciences Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - beatles.ru
Is Senti Biosciences Inc. a good long term investmentRemarkably fast returns - PrintWeekIndia
What drives Senti Biosciences Inc. stock priceFastest-growing stock picks - jammulinksnews.com
Senti Bio Appoints Bryan Baum to Board of Directors, Aims for Growth with New Expertise. - AInvest
Senti Biosciences Appoints Bryan Baum to Board, Enhancing Strategic Direction and Optimizing Value for Stakeholders - AInvest
Bryan Baum Joins Senti Biosciences Board of Directors - AInvest
Senti Biosciences Inc. Stock Analysis and ForecastHigh-impact investment strategies - Jammu Links News
Sweetgreen, Inc. shares rise 3.77% intraday after Senti Biosciences, Inc. appoints Bryan Baum to its Board of Directors. - AInvest
Senti Biosciences Appoints Bryan Baum to Board - TipRanks
Senti Bio appoints K5 Global co-founder Bryan Baum to board of directors - Investing.com
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors - The Manila Times
OpenAI and SpaceX Investor Bryan Baum Joins Senti Bio to Transform Cancer Treatment with Gene Circuits - Stock Titan
Is Senti Biosciences Inc. stock overhyped or has real potentialLow Risk ROI Maximization - Newser
How Senti Biosciences Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
What makes Senti Biosciences Inc. stock price move sharplyFree Consultation - Newser
SNTI’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Senti Biosciences Stock Faces Decline Amid Market Challenges - timothysykes.com
Senti Biosciences Soars 32.39% on Promising Clinical Trial Results - AInvest
Senti Biosciences (NASDAQ:SNTI) Upgraded by Wall Street Zen to “Sell” Rating - Defense World
Senti Biosciences (NASDAQ:SNTI) Trading Up 2.5% – Here’s What Happened - Defense World
Senti Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Senti Bio Participates in Nasdaq Amplify Spotlight Series - TradingView
Senti Biosciences, Inc.(NasdaqCM: SNTI) added to Russell 3000E Value Index - MarketScreener
SNTI SEC FilingsSenti Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Is Senti Biosciences, Inc. overvalued or undervalued? - MarketsMojo
Senti Bio Reveals Next-Gen Logic-Gated Cell Technology for Precision Cancer Treatment at SEED 2025 - Stock Titan
FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML - Targeted Oncology
Senti Biosciences Inc (SNTI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment - MarketScreener
Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation - Nasdaq
FDA grants orphan drug designation to Senti Bio’s AML treatment - Investing.com
FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes - Stock Titan
Senti Biosciences Soars 7.91% on FDA Orphan Drug Designation - AInvest
Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan Capital - Defense World
Senti Biosciences (SNTI) Rating and Price Target Updated by Chardan Capital | SNTI Stock News - GuruFocus
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Gene Circuit Pioneer Senti Bio Grants $310K in Stock Options to Expand Next-Gen Therapy Team - Stock Titan
Laidlaw Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc.SNTI - WV News
SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. | SNTI Stock News - GuruFocus
Laidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation - Nasdaq
SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. - GuruFocus
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - The Manila Times
Exclusive: Senti Bio Leaders Reveal Next-Gen Cell Therapy Vision in Chardan Fireside Discussion - Stock Titan
Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target - GuruFocus
Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target | SNTI Stock News - GuruFocus
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):